Eric L. Nuermberger

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

This study identifies Rv2061c as a critical F420-dependent oxidoreductase that protects Mycobacterium tuberculosis from antimicrobials and oxidative stress.

This study evaluates the efficacy of a single dose of long-acting sorfequiline in a mouse model for tuberculosis preventive therapy.

This study evaluates TBD09's contribution to BPa-based tuberculosis regimens in mice, showing comparable bactericidal and sterilizing activity to linezolid with reduced toxicity.

The paper develops a predictive model to rank tuberculosis regimens by relapse prevention using 28-day CFU and RS ratio data from a relapsing mouse model.

BCG therapy reduces tau pathology and improves cognitive function in PS19 mice by modulating myeloid cell activity and neuroinflammation.

A DNA vaccine targeting Mtb persisters reduces TB treatment duration in mice and elicits similar immune responses in macaques.

This paper predicts the early bactericidal activity of tuberculosis drug combinations using a translational PK-PD modeling approach, showing consistent interaction patterns and reliable predictions for clinical outcomes.

This study develops SABER hydrogels that extend drug release and therapeutic effect for small molecules and biologics in preclinical models.

This study evaluates telacebec's contribution to combination therapies against two M. tuberculosis strains in a murine model, finding synergistic effects against HN878 and antagonistic effects against H37Rv.

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

This study validates cwlM and pbpB as essential genes for Mycobacterium abscessus viability and imipenem resistance using CRISPRi in vitro and in vivo.

This study evaluates how hyaluronidase affects the release and pharmacokinetics of a long-acting injectable drug in mice and rats.

This study identifies mutations in Mycobacterium tuberculosis that confer resistance to nitroimidazole antibiotics, highlighting the need for monitoring these mutations to manage antibiotic use.

This paper identifies Rv2983 as a novel gene conferring resistance to nitroimidazole drugs in Mycobacterium tuberculosis and highlights the challenges in detecting such resistance.

This study establishes a murine model of progressive Mycobacterium abscessus lung infection under corticosteroid treatment, demonstrating its progression to pathology.